Treatment of Severe XXXX in ANCA Positive and Negative Small @entity1333 with Rituximab.

@entity1 @entity8 @entity1333 @entity786 @entity454
BACKGROUND/AIMS: Rituximab and glucocorticoids are a non-inferior alternative to @entity786 and glucocorticoid therapy for induction of remission in antineutrophil cytoplasmic antibody (ANCA) associated @entity1333 (AAV) @entity1 with moderate @entity8 . The efficacy and safety of this approach in @entity1 with severe @entity8 are unknown. We report the outcomes and safety profile of rituximab and glucocorticoid therapy for induction of remission in @entity1 with AAV and ANCA-negative @entity1333 presenting with severe @entity8 . METHODS: A multicenter, retrospective, cohort study was conducted between 2005 and 2014. @entity1 with new or relapsing disease with an estimated glomerular filtration rate (eGFR) of  <=20 ml/min/1.73 m(2) treated with rituximab and glucocorticoid induction with or without plasmapheresis were included. Fourteen @entity1 met the inclusion criteria. The primary outcomes were rate of remission and dialysis independence at 6 months. The secondary outcomes were eGFR at 6 months, @entity454 ( @entity454 ), survival rates and adverse events. RESULTS: All @entity1 were Caucasian, and 57% were male. The mean eGFR was 12 ml/min/1.73 m(2) at diagnosis. All @entity1 achieved remission with a median time to remission of 55 days. Seven @entity1 required dialysis at presentation of which 5 @entity1 recovered renal function and discontinued dialysis by 6-month follow-up. The mean eGFR for the 11 @entity1 without @entity454 who completed 6-month follow-up was 33 ml/min/1.73 m(2). Four @entity1 ultimately developed @entity454 , and one died during the follow-up period. CONCLUSION: @entity1 with AAV and severe @entity8 achieve high rates of remission and dialysis independence when treated with rituximab and glucocorticoids without @entity786 .    2015 S. Karger AG, Basel.
